Chemo-immunotherapy regimen with gemcitabine + FOLFOX 4 (GOLF) followed by subcutaneous (sc) granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2). Results from a multicenter phase II trial in colon carcinoma patients

Pierpaolo Correale,Cinzia Remondo,Francesco Montagnani,Maria Saveria Rotundo,Stefania Marsili,M. LaPLACA,P. Tassone,P Tagliaferri,Salvatore Venuta,Guido Francini

Chemo-immunotherapy regimen with gemcitabine + FOLFOX 4 (GOLF) followed by subcutaneous (sc) granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2). Results from a multicenter phase II trial in colon carcinoma patients

2006

Pierpaolo Correale
Cinzia Remondo
Francesco Montagnani
Maria Saveria Rotundo
Stefania Marsili
M. LaPLACA
P. Tassone
P Tagliaferri
Salvatore Venuta
Guido Francini

3587 We have recently described a poly-chemotherapy (GOLF) regimen that: A) is active in colon carcinoma patients as second line of therapy; B) induces high levels of necrosis and apoptosis in colo...

Keywords:

Carcinoma
Gemcitabine
Regimen
Immunotherapy
Interleukin 2
FOLFOX
Cancer research
Surgery
Granulocyte macrophage colony-stimulating factor
Medicine
Physical therapy
Necrosis
colon carcinoma
Apoptosis
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations